Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
United States
University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, California Dana Farber Cancer Research Institute, Boston, Massachusetts University of Michigan Rogel Cancer Center, Ann Arbor, Michigan Memorial Sloan Kettering Cancer Center, New York, New York Sarah Cannon Research Institute, Nashville, Tennessee